TAVO412 for advanced solid tumors with EGFR, MET, or VEGF changes
Part of Cancer clinical trials.
This trial tests a new drug, TAVO412, for people with advanced solid tumors that have not responded to other treatments. It focuses on cancers with specific markers (EGFR, MET, or VEGF) and aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with advanced cancer that has not responded to standard treatments.
- You need to have an ECOG performance status of 0 or 1, meaning you are fully active or able to do light work.
- Your cancer must have specific genetic changes or protein levels in EGFR, MET, or VEGF (for the second phase).
- You must be willing to have blood tests and possibly a tumor biopsy (for the second phase).
- You cannot have certain heart conditions, active infections, or other serious illnesses that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
This trial tests a new investigational drug, TORL-4-500, for people with advanced solid tumors that have not responded to other treatments. It aims to find a safe dose and see if the drug can help shrink or control the cancer.
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.